A 28-year-old woman with known HIV infection (CD4 count 180 cells/μL) presents with a 2-week history of cough and dyspnea. Chest X-ray shows bilateral lower-lobe infiltrates with minimal cavitation. Sputum smear microscopy is negative on three occasions. GeneXpert MTB/RIF is positive for Mycobacterium tuberculosis (rifampicin-sensitive). What is the most appropriate next step?

Explanation

## Clinical Context This patient has: - Microbiologically confirmed TB (GeneXpert MTB/RIF positive) - Advanced HIV (CD4 < 200 cells/μL) - Smear-negative pulmonary TB (SNPT) - Rifampicin-sensitive organism ## Key Principle: Molecular Confirmation Overrides Smear Status **High-Yield:** GeneXpert MTB/RIF is WHO-endorsed as the first-line diagnostic test for TB in HIV-positive patients. A positive GeneXpert result is sufficient to diagnose TB and initiate therapy, regardless of smear status. Smear-negative TB is common in advanced HIV (CD4 < 200) due to impaired immune response and reduced bacterial load in sputum. **Key Point:** In smear-negative, GeneXpert-positive TB: - Diagnosis is confirmed - ATT must begin immediately to prevent disease progression - Delayed treatment increases mortality risk in advanced HIV ## TB-HIV Co-management: Timing of ART ```mermaid flowchart TD A[TB-HIV Co-infection]:::outcome --> B{CD4 count?}:::decision B -->|CD4 < 50 cells/μL| C[Start ATT first]:::action C --> D[Start ART within 2 weeks]:::action B -->|CD4 50-200 cells/μL| E[Start ATT first]:::action E --> F[Start ART within 2 weeks]:::action B -->|CD4 > 200 cells/μL| G[Start ATT + ART together]:::action D --> H[Monitor for TB-IRIS]:::action F --> H G --> I[Standard TB-HIV management]:::outcome ``` **Clinical Pearl:** In advanced HIV (CD4 < 200), ATT is initiated first, followed by ART within 2 weeks. This sequence: - Reduces risk of TB-IRIS (immune reconstitution inflammatory syndrome) - Allows immune system stabilization before ART-induced immune activation - Prevents overwhelming opportunistic infection if ART is delayed - WHO/NACO guidelines recommend ART initiation within 2 weeks of ATT start ## Why Option 1 Is Correct Standard first-line ATT (HRZE) is initiated immediately upon GeneXpert confirmation. ART is started after 2 weeks of ATT, which: 1. Allows initial TB treatment response 2. Reduces TB-IRIS risk 3. Permits immune stabilization 4. Follows WHO and NACO TB-HIV guidelines | Parameter | Action | Timing | |-----------|--------|--------| | GeneXpert MTB/RIF result | Start ATT (HRZE) | Day 0–1 | | Baseline CD4 < 200 | Defer ART | 2 weeks | | ART initiation | Integrase inhibitor–based regimen | Week 2 | | Monitoring | TB-IRIS surveillance | Ongoing | **Mnemonic:** **IRIS Risk Factors** = **CD4 < 50**, **TB burden**, **Recent TB diagnosis**. Delaying ART by 2 weeks in advanced HIV reduces IRIS incidence.